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ABSTRACT 
Anusha Smith: Development of a Practice Protocol for the Use of Long Acting Injectable 
Antipsychotic Medications in the Emergency Department 
(Under the direction of Cheryl Giscombe) 
 
Background: Long acting injectable antipsychotic (LAI) medications were developed to 
improve adherence in patients with psychotic disorders. Studies have shown patient on these 
medications have reduced inpatient admissions and Emergency Department (ED) visits. Aim: To 
develop a practice protocol which identifies patients who could benefit from a long acting 
injectable while in the ED setting. The goal of the project was to educate the providers about 
how to use the long acting injectable antipsychotic medications in their treatment plans and 
provide tips on how to have a discussion with the patient. Methods: A quality improvement 
project which educates mental health providers in the ED about the practice protocol and how to 
implement it through a 1.5-hour education session. Data from 20 charts were collected from 
chart reviews of the electronic record.  At the completion of the data collection, a group 
interview was conducted to gather feedback from the providers about the protocol. Results: Of 
the 20 patients who received the protocol, eight of those patients received the LAI while in the 
ED. During the interview, Providers were discussing the option of the LAI more consistently. 
While they felt their knowledge about LAIs did not increase, they did feel the protocol prompted 
them to have the discussion. Conclusion: The findings suggest the practice protocol can increase 
awareness, provide guidance regarding treatment and increase utilization of LAIs in the ED 
setting.   
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CHAPTER 1: AVOID REINVENTING THE WHEEL 
Introduction 
The care of people with mental health illnesses has changed over the past 60 years. 
People who were unable to care for themselves were treated for years in mental health 
institutions. As the financial burden for caring for people mental health diagnoses increased, 
states focused on returning them to the communities through deinstitutionalization (Koyanagi, 
2007). However, there was a lack of community resources to maintain this population 
appropriately in the communities. As these problems became apparent, states moved to funding 
community-based supports which included community psychiatric hospital beds (Koyanagi, 
2007). However, many of these supports were not equipped to the effectively manage people 
with mental illness. Thus, community systems such as jails, prisons and Emergency Departments 
(EDs) have been providing care for them (Torrey Fuller, Geller, Jacobs & Ragosta, 2012). 
North Carolina, as well as much of the nation, is suffering from a lack of inpatient 
psychiatric hospital beds. Per the North Carolina Center for Public Policy Research (NCCPPR), 
North Carolina lost 214 inpatient state psychiatric beds statewide from 2000 to 2010 (NCCPPR, 
2012). State hospitals reduced the number of patients treated from 16,789 to 5,754 during 2000 
to 2011 (NCCPPR, 2012). The lack of inpatient psychiatric beds has had a direct impact on wait 
times in EDs. North Carolina Department of Health and Human Services found patients waiting 
an average of 4.6 days in EDs for a bed in an inpatient psychiatric hospital (2015).  Psychiatric 
patients are in the ED for extended periods of time, also known as boarding, while waiting for 
admission to a psychiatric service as there is a nationwide decrease in the number of inpatient 
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psychiatric beds (Torrey et al., 2012). Psychiatric boarding is defined as a waiting period 
of more than 4 hours in the ED for a psychiatric bed once the decision is made to admit a patient 
(American College of Emergency Physicians, 2014). One study estimates the total cost of 
psychiatric boarding which includes other patients who could have been treated during the time a 
psychiatric patient is boarding in an ED bed is about $2,264 (Nicks & Manthey, 2012).  
  Psychiatric boarding has significantly increased and ED directors are citing gaps in 
inpatient hospital beds and outpatient psychiatric programs as contributing factors (The Joint 
Commission, 2015). The Joint commission lists consequences of boarding which include; 
increases psychological stress, delays in mental health care, increases ED crowding, delays 
treatment for other ED patients and decreases financial reimbursement for ED services (The 
Joint Commission, 2015).  ED overcrowding and increased wait times for psychiatric patients are 
symptoms of larger systems issues which illustrate the lack of community resources.    
The American College of Emergency Physicians (ACEP) recommends treatment 
protocols for psychiatric patients in the ED, but there has been little research around what 
protocols would be beneficial, particularly with chronic mental health disorders which have high 
rates of relapse and rehospitalization, like schizophrenia (2014). Given the long waiting periods 
for patients with mental health needs, their presence in ED provides a greater need to develop 
protocols to both provide treatment to patients in a timely fashion and investigate opportunities 
to improve their outcomes while in the ED setting.   
Patients with schizophrenia or other psychotic disorders account for about 34.9% of ED 
visits for a psychiatric complaint (Downey & Zun 2015).  Approximately 22% of patients with 
schizophrenia were readmitted to the hospital within a month after being discharged (Elixhauser 
& Steiner, 2010).  The lack of psychiatric beds has increasingly compelled ED staff to shift from 
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evaluation to beginning immediate treatment in the ED rather than delaying pharmacologic 
management. Inpatient treatment options for patients with schizophrenia include administration 
and monitoring of antipsychotic medications to reduce symptoms of psychosis (Oliveres, 
Sermon, Hemels & Schriener, 2013). The use of antipsychotic medications have been shown to 
decrease the need for hospitalization and a reoccurrence of symptoms (Olivares, Sermon, Hemels 
&Schriener, 2013).   
Poor medication adherence is one of the most common precipitant of re-hospitalization in 
patients with schizophrenia (Caseiro, Perez-Iglesias, Mata, et al 2012).  To address the issue of 
adherence and relapse, inpatient psychiatric hospitals have increased the use long acting 
injectable antipsychotic medications (LAIs) (MacEwan et al., 2016).  In a study of readmission 
rates in patients with schizophrenia, patients placed on long acting injectable antipsychotic 
medications had a 5% lower rate of hospital readmissions at 60 days post hospitalization 
(MacEwan et al., 2016).   
Initiating treatment in the ED for patient with psychosis serves to reduce agitation and 
improve the safety for staff and the patient. An observational study of patients who presented to 
the ED for a psychiatric complaint, found that patients with psychosis had significantly higher 
scores on the Agitation Severity Scale and the Overt Agitation Severity Scale (Stroud & 
Bauman, 2015).  Another study of agitation in ED and Acute Inpatient Units (AIUs), found that 
about 50% of incidents of agitation were in patients with a diagnosis of schizophrenia (San, et 
al., 2016). Given this, it is reasonable to consider beginning or resuming scheduled antipsychotic 
medications in the ED setting to reduce agitation, provide treatment, and reduce the need for an 
inpatient psychiatric hospital if possible while awaiting a psychiatric bed.  
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Nursing Significance 
 This DNP project hopes to improve the care of psychiatric patients in the ED. Nursing is 
in a unique position to examine clinical issues from a systems perspective and utilize evidence-
based practice to develop clinical protocols for specific settings such as the ED. The American 
Association of Colleges of Nursing outlines eight essential goals for advanced practice nurses 
which were used to guide the DNP project (2006). By applying evidence-based nursing practice 
in conjunction with a holistic view of the clinical problem, nursing can assume more of a 
leadership role in the clinical setting and meet Triple Aim Goals (Institute of Medicine, 2001). 
Purpose 
 In summary, due to the decrease in available inpatient psychiatric beds, patients remain in 
the ED longer and initiating treatment earlier in their ED stay may reduce symptoms and 
decrease the need for inpatient hospitalization.  Therefore, the purpose of this DNP project is to 
develop a protocol for patients presenting to the ED with psychotic disorders to guide treatment 
planning through the initiation of antipsychotic medications which may be transitioned to an 
LAI. This protocol will also assist mental health providers in identifying patient in the ED who 
would be best suited for the implementation of this protocol.
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CHAPTER 2: REVIEW OF LITERATURE 
The review of literature focused on effectiveness of long acting injectable antipsychotic 
medications and associated themes related to adherence in people with schizophrenia. The 
findings from this review was used to provide support for the development of protocols for the 
use of LAIs in the ED, the goal of DNP project. LAI medications can be effective for varying 
lengths of time, from 2 weeks up to 3 months. In people with schizophrenia, poor adherence 
leading to relapse is concern. LAIs were developed to help address this concern and recent 
studies have sought to evaluate the effectiveness of these medications.  
 Methodology and Results for Review of Literature 
 PubMed, PsycInfo and CINAHL were the search engines used to identify articles. Search 
limitations included English and human subjects. There were no limits placed on time or date.   
The search terms “antipsychotic medications AND emergency departments” yielded 83 results 
most of which did not apply to the research question.  Therefore, search terms were changed to 
“schizophrenia AND readmission” which provided inpatient interventions to prevent 
readmissions in patient with schizophrenia.  Search was adjusted to “long acting injectable 
antipsychotic medications AND readmission” this yielded about 21 articles. Search was adjusted 
to “Long acting injectable antipsychotics AND adherence AND schizophrenia” which yielded 
184 articles. Forty articles were reviewed and 25 articles were included in the review of 
literature.  
The following review highlights a few articles from each theme identified in the 
literature. Two articles discussed patient’s perception of LAIs and five articles were explored 
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regarding prescribers view of LAIs. Seven studies were included in the comparison 
between oral antipsychotic medications and LAIs. Four studies were reviewed readmission rates 
of patients on LAIs. 
Theme 1: Adherence and Effectiveness 
 Schizophrenia is a complex psychiatric disorder which affects a person’s ability to 
maintain safety, stability and independency in the community. There are a multitude of factors 
which contribute to a person’s ability to function in the community. When providing treatment 
for a condition, often treatment focuses on medication effectiveness and its ability to reduce 
symptoms. However, this is one piece of the puzzle when working with people who have a 
psychiatric diagnosis. Poor adherence is often cited as a concern for this population and a 
hindrance to medication effectiveness. It often leads to a reoccurrence of symptoms and 
decompensation which requires an intervention such as hospitalization. The development of 
LAIs was undertaken to address this and to assure adherence.   
The Agency for Healthcare Research and Quality (AHRQ) outlines several 
recommendations regarding the use of long acting antipsychotic medications through clinical 
guidelines developed through various international entities. For example, the Scottish 
Intercollegiate Guidelines Network recommends evaluating patient preference for injections as 
well as reviewing risks and benefits of LAI medication (AHRQ, 2013). The guideline suggests 
LAIs may improve adherence in patients who have repeated relapses on oral antipsychotics and 
should be considered at a high risk for a reoccurrence of symptoms and repeated hospitalizations 
(AHRQ, 2013). The following themes investigate factors which contribute to LAI effectiveness 
including patient and prescriber perceptions of LAIs, reduction of symptoms, reduced 
hospitalizations and effectiveness when compared to oral antipsychotic medications.  
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Theme 2: Patient Perceptions of LAIs 
 People who have a diagnosis of schizophrenia often face an uphill battle when managing 
their symptoms. The stigma of mental illness and the cognitive effects of the disease can 
influence how someone views treatment and medication effectiveness. Patient perceptions play 
an important role in adherence and by understanding these perceptions, clinicians can work to 
address patient concerns regarding LAIs.  
In a study by Heres, Schmitz, Luecht and Pajonk, 300 patients diagnosed with 
schizophrenia and placed on a LAI were surveyed about attitudes towards drug treatment (2007). 
Of all the patients surveyed 54% of the patients found taking an LAI was more convenient than 
taking oral medications. About 43% of patients surveyed felt LAIs prevented relapse more 
effectively. Conversely, 18.9% felt the LAI was mandatory treatment and they did not have 
choice because of their frequent relapses (Heres, Schmitz, Luecht and Pajonk 2007).  
      Iyer and colleagues conducted a qualitive study with focus groups to evaluate patient 
experiences and perceptions about LAIs (2013). This sample included 34 patients with a 
diagnosis of schizophrenia spectrum psychosis (Iyer et al., 2013).  In the study group, 67% of the 
group had either been on or were currently on an LAI. Among the rest of the group, 26.47% had 
not been offered an LAI (Iyer et al., 2013). Several other members of the group had been offered 
an LAI, but did not feel they understood the purpose or benefits of LAI (Iyer et al., 2013). 
Patients discussed the positives of being on an LAI which included increased perception of 
control, consistent dosage, better symptom management and less side effects. Disadvantages 
included longer time to see reduction of symptoms, breakthrough psychosis, increase number of 
appointments, cost and feeling tied to clinic to get injections (Iyer et al., 2013). Patients who had 
8 
no experience with LAIs viewed it as a “punishment’ for poor adherence and less control over 
dose as other disadvantages (Iyer et al., 2013).  
     These articles highlight the diverse perceptions patients have regarding their treatment. 
Despite the varied responses of the participants, the majority felt LAIs were beneficial in terms 
of both a clinical reduction of symptoms and personal quality of life. The Iyer and colleagues 
study identified a lack of knowledge regarding LAIs in a significant number of patients who 
could possibly benefit from being on an LAI. Negative perceptions can be addressed through 
education which equips patient with the knowledge to make choice for themselves and good 
communication with providers. Understanding these barriers is key to providing patient centered 
care and to improve adherence to medications. 
Theme 3: Prescriber practices and views about LAIs 
   While patient preference is essential to adherence, the perceptions of prescribers also play 
a major role in providing the patient choices for treatment. Providers guide treatment and 
provider treatment options for patients so their perceptions influence how they develop their 
treatment plan for the patient. It is widely recognized that people with schizophrenia have 
relapses and poor adherence to their prescribed oral antipsychotic is one of the main causes of 
this. However, prescribers have cited several concerns about using LAIs which has led to a 
preference for oral antipsychotics despite the higher rate of relapse associated with oral 
medications. Prescribers report a lack of evidence for the superior effectiveness of LAIs as 
research shows LAIs provide similar effectiveness when compared to oral antipsychotic 
medications so prescribers are less inclined to use LAIs (Correll et al, 2016). However, many 
studies focus on effectiveness when a patient consistently takes their medications which if often 
not the case in patients with psychotic disorders (Correll et al., 2016). Prescribers cited a lack of 
9 
knowledge regarding use of LAIs, dosing and how to manage persistent symptoms after starting 
LAI (Correll et al, 2016). There is a belief LAIs have a greater side effect profile than their oral 
counter parts which is unfounded (Correll et al, 2016). In addition, prescribers were concerned 
about suggesting LAI, since LAI treatment may be viewed as coercive by patients (Correll et al, 
2016). There are no clinical restrictions in the guidelines regarding the use of LAIs in 
populations who may be at risk for relapse but have not demonstrated poor adherence which may 
contribute to hesitation when prescribing LAIs (AHRQ). These perceptions influence treatments 
that are offered and takes the decision-making power from patients.  
 In a qualitative study by Iyer et al, prescriber practices were explored through focus 
groups with 24 psychiatrists. Prescribers indicated they prescribed oral antipsychotic medications 
most often (Iyer et al., 2013).  Of the 24 psychiatrists, 8 prescribed LAIs often while 12 rarely 
prescribed LAIs (Iyer et al., 2013). The major theme identified in the focus groups was a “lack of 
knowledge” regarding the use of LAIs (Iyer et al., 2013). Prescribers also felt patients may 
perceive LAIs as coercive and felt patients will refuse treatment with LAIs and they did not offer 
it as an option for treatment (Iyer et al., 2013).  Prescribers viewed LAIs as a medication of last 
resort with patients who have repeated relapses due to poor adherence (Iyer et al., 2013).  
Prescribers perceive patients on LAI’s as patients with chronic severe disease which may 
be difficult to treat. This perception is corroborated through several studies. In a study, which 
followed 6904 people who were new started on oral antipsychotic medications for 7 years and 
only 4.1% had an LAI initiated during the study period (Verdoux, Pambrun, Tournier, Bezin & 
Pariente, 2016). The average time from starting an oral antipsychotic to transitioning to an LAI 
was about 19.3 months (Verdoux et al, 2016). In another study, about 90% of psychiatrists 
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transitioned their patients primarily to LAIs to improve adherence as those patients were non-
adherent to oral medications (Bayle, Tessier, Bouju & Misdrahi, 2015).     
      Prescribers are primarily responsible for developing a treatment plan in collaboration 
with patients. By identifying negative perceptions which influence prescribing practices, future 
research could work towards improving prescriber education regarding the use of LAIs. 
Prescribers can also provide education needed to reduce stigma related to LAI treatment.  
Theme 4: LAIs and Oral Antipsychotics: A comparison 
  AHRQ guidelines recommend antipsychotic medications for all patients who have been 
diagnosed with schizophrenia (2013). This guideline also rates LAIs as effective as oral 
antipsychotic medications in controlled studies. Current researchers have been looking at the 
effectiveness of LAIs from different perspectives because people with schizophrenia are not in 
controlled research settings so poor adherence continues to be an issue. A study by Alphs et al. 
discussed the difference between explanatory trials which are focused on safety and effectiveness 
and pragmatic trials or “real world trials” which minimize exclusionary criteria so diverse patient 
populations can be studied (Alphs et al., 2014). Pragmatic studies are designed to evaluate 
outcomes that are identified by clinician and their patients and often include scales which assess 
patient reports of symptom reduction and side effect reports (Alphs et al., 2014).   
 A study compared effectiveness of oral antipsychotics and LAIs through three measures: 
Positive and Negative Syndrome Scale (PANSS), Personal and Social Performance Scale (PSP) 
and hospital readmission rates (Barrio et al., 2012). Both groups showed improvement in the 
PANSS and PSP scores, however the LAI group had significantly greater improvement of 
symptoms compared to oral antipsychotic medications (Barrio et al., 2012). While statistically no 
difference in rehospitalization rates, LAI group had a fewer number of readmission during the 2 
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year study period (Barrio et al., 2012). Throughout the literature search there were few studies 
which looked a reduction of symptoms as a measure of effectiveness which may contribute to 
prescriber views that oral medications are as effective as LAI medications.   
 A study, which compared relapse rates between LAI and oral antipsychotics, found there 
were no significant differences between the groups over the 30-month study period (Buckley, et 
al., 2015). There was a significant decrease in relapse rates in both groups (Buckley et, al., 
2015). Another study followed two groups of patients on LAI and oral antipsychotics for 3 years 
and found no statistical difference between the groups (Liu et al., 2012). Both studies are 
representative of the studies used to develop guidelines and recommendations about the use of 
LAIs. 
 Several studies have looks at re-hospitalization rates between LAI and oral antipsychotic 
groups through Medicaid claims data. This allows for a review of larger groups of patients, 
medications, and number of hospitalizations. In study of 8,620 patients, patients were followed 
for 30 days post hospitalization and monitored readmission rates (Marcus, Zummo, Pettit, 
Stoddard & Doshi, 2015). Results found a decrease of 33% readmission rates of patients taking 
an LAI (Marcus et al., 2015).  Another study found a reduction in readmission at a rate of 5% in 
patients who have had an LAI within 60 days after discharge (MacEwan et al., 2016). A study 
used Premier Hospital Database to look at mental health hospitalization rates, all hospitalization 
rates and ED visits in patients with schizophrenia (Lafeuille et al., 2013). Results demonstrated a 
12-19% decrease in both all hospital admissions and ED visits in patients on LAIs (Lafeuille et 
al., 2013). A systematic review of mirror image studies comparing LAIs with oral antipsychotic 
medication found LAIs were more effective in preventing hospitalization, decreasing the number 
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of hospitalizations and reducing length of stay for patients who were hospitalized (Kishimoto, 
Nitta, Borenstien, Kane & Correll, 2013).    
 Studies, which have been described as real-world studies or pragmatic studies, have 
consistently shown a decrease in the readmission rates in patients who take LAIs. Few adverse 
events were noted in these studies. Even in randomized control trials, LAIs were shown to be as 
effective as oral antipsychotic medication.  Many of these studies were retrospective in nature 
and a causal relationship could not be determined, however, the decreases which were noted in 
the LAI group illustrate the need for further research regarding LAIs.  
Theme 5: Readmission Rates in Patients Taking LAIs 
 The development of the LAI was aimed at targeting adherence as poor adherence was a 
strong predictor of relapse in people with schizophrenia. Studies have monitored people who are 
on a LAI over time to determine if LAIs reduced relapse through adherence and when compared 
to relapse rates prior to LAI initiation. Overall, these studies have found reductions in hospital 
admissions, increased time between relapses and increased adherence.   
 In a retrospective study of 3,094 Medicaid patients with schizophrenia who were started 
on an LAI, all hospitalization rates decreased by 24.2% (Kamat et al., 2015). These patients were 
monitored before and after LAI initiation (Kamat et al., 2015). There was also a significant 
decrease in hospital costs from between $2,051-$4,492 per year (Kamat et al., 2015).  Another 
retrospective study found the longer a patient is on an LAI the greater the reduction in all 
hospital admissions, including mental health (Bera et al., 2014).  
 A three year follow up study found a significant difference is relapse rates between 
patients who were adherent to LAIs versus those who were non-adherent (Caseiro et al., 2012). 
Patients who were adherent had a relapse rate of 50% while non-adherent patients had a relapse 
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rate of 93.7% (Caseiro et al., 2012). The time between relapses was also significantly different, 
933 days for adherent and 568 days for non-adherent patients (Caseiro et al., 2012).  
 A study done through the Veterans Administration (VA) system studied the use of health 
care services in veterans with schizophrenia who were placed on a LAI (Ren et al., 2010). The 
data were collected from administrative data and pharmacy data within the VA system (Ren et 
al., 2010). Patients were followed for 12 months prior to LAI initiation and for 12 months post 
initiation (Ren et al., 2010).  The study found patients who had at least one or two psychiatric 
hospitalizations prior to LAI decreased from 68.9 % to 45.7% after LAI initiation (Ren et al., 
2010).  
 As the LAI and oral comparison studies discussed previously, many of these studies were 
retrospective in nature. These studies appear to imply that the use of LAIs have improved 
adherence and therefore there is a reduction in relapse rates in patients using an LAI. The 
reduction on costs associated with caring for patients with schizophrenia have long been a 
concern and interestingly there were cost reductions related to the use of LAIs. These cost 
savings included not only treatment for psychiatric conditions, but medical conditions as well. 
While there appears to be a link between LAIs and a reduction in relapse rates as well, several 
factors may be influencing this reduction. Patients who are on LAIs must follow up more 
regularly and this may be a contributing factor to the perceived improvement in patient 
outcomes. There is a lack of knowledge regarding additional community supports the patient 
may have which improve adherence and stability. There continues to be a need to research 
effectiveness of LAIs and relapse rates. 
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Summary and Conclusions from Literature Review  
 There are multiple factors which contribute to relapse in patient with schizophrenia. 
However, the use of antipsychotic medication has been shown to reduce psychotic symptoms and 
decrease the need for inpatient hospitalization. Poor medication adherence is one of the leading 
factoring in relapse rates in this population. LAI medications have not been shown to be more 
effective in improving adherence as patient still have to get the injections to remain stable, but 
there have been several studies which have shown a decrease in both ED visits and need for 
inpatient psychiatric hospitalization for safety and stabilization. The AHRQ guidelines do not 
limit the use of LAIs in this population and defer to the provider and patient preference for 
initiating an LAI. 
 Studies have identified barriers to prescribing an LAI as well. Providers have been 
hesitant to prescribe LAIs because they perceive LAIs are for patients who have more severe 
disease or are non-adherent to oral medications. This perception often leads to providers 
avoiding discussing the LAI with the patient. Studies have shown some patients can also 
perceive LAIs this way, however other feel that LAIs make it easier for them to avoid relapse.  
 These studies illustrate a gap in the knowledge about utilizing LAIs for treatment of 
patients with psychotic disorders. With an increase in education of both patients and providers, 
there could be better patient outcomes which continue to engage the patient the management of 
their mental health condition. It would also serve to help reduce the stigma of mental health 
conditions and how they are treated.       
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CHAPTER 3: THEORETICAL FRAMEWORK AND METHODOLOGY 
 This DNP project started as concern about providing quality psychiatric care for patients 
in the ED setting as boarding for these patients started to increase due to a lack of psychiatric bed 
availability. While working with patients, it became apparent there many contributing factors for 
patients needing psychiatric evaluation. It was often a combination of needing medication 
management and psychosocial factors such as housing, insurance and access to mental health 
care. Patient with psychotic disorders are often more difficult to place due to chronic nature of 
their condition or history of aggression related to their psychosis and therefore have longer ED 
stays. When conceptualizing how to approach this clinical issue, a systems approach was utilized 
to ensure the practice changes being implemented would be sustainable. Treatment with LAIs 
requires more treatment planning as community providers needs to be able to continue 
administering LAIs on discharge.   
 Recovery Oriented Care 
The Recovery- Oriented Systems of Care is somewhat unusual as there is not a single 
founder, however there are several people from a wide range of disciplines who helped shape the 
theory.  The theory was built from defining the term “recovery” and how to relates to the 
experiences of people who are in recovery.  The term “recovery” in health care is thought of as 
returning to the state health you were in prior to your illness or “cure” (Whitwell, 1999).  There 
has been a shift in how professionals, particularly mental health professionals, view recovery.  
Recovery is viewed as being on a continuum rather than an endpoint. Anthony describes 
recovery as “deeply personal, changing ones’ attitudes, values and feelings” (1993).  Deegan 
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describes recovery as a “process” and “a series of small beginnings and small steps” 
(1988).  The Substance Abuse and Mental Health Services Administration (SAMHSA) initially 
focused on recovery as it related to substance abuse treatment, but it was not until 2012 when 
mental health was added to the recovery model and encouraged the use recovery-oriented 
treatment in mental health disorders (SAMHSA, 2012).  
The recovery- oriented systems of care theory is descriptive theory which reframes the 
term recovery and put forth a set of ideals on how to care for people with substance abuse and 
mental health issues. Recovery oriented care moves away from the traditional medical model, 
which looks at pathology, symptoms and treatment, and highlights a person-centered focus 
(Roberts & Wolfson, 2004).  The process of recovery focuses on personal growth and adaptation 
related to challenges of having a psychiatric illness (Roberts & Wolfson, 2004). Core principles 
emerge from the concept that recovery is “person driven” (SAMHSA, 2012). The person is the 
“expert by experience” and professionals provide guidance, but do not direct treatment (Roberts 
&Wolfson, 2004). The person defines what recovery looks like for them and identifies supports 
and needs moving towards their recovery (SAMSHA, 2012).   
Recovery Oriented Care and LAIs  
In a review the literature, studies assert the use of LAIs have improved medication 
adherence and therefore there is a reduction in relapse rates in patients using an LAI. The 
reduction on costs associated with caring for patients with schizophrenia have long been a 
concern and interestingly there were cost reductions related to the use of LAIs. Agency for 
Healthcare Research and Quality (AHRQ) guidelines recommend antipsychotic medications for 
all patients who have been diagnosed with schizophrenia (2013). This guideline rates LAIs as 
effective as oral antipsychotic medications when compared in controlled studies but not as a first 
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line treatment (AHRQ, 2013). This guideline leaves the decision to start an LAI with the 
provider as there is no evidence to show that an LAI would be more effective than its oral 
counterparts. AHRQ does not preclude a provider from utilizing an LAI as a first line treatment, 
alongside oral antipsychotics as a first line treatment.     
This DNP project was conceptualized from a systems perspective to investigate barriers 
in using LAIs and if expanding their use to other clinical settings would increase their use and 
improve outcomes for this population. Mental health treatment is complex and needs to be 
wholistic in nature as many factors influence treatment. Research has sought to quantify 
outcomes for this population to evaluate treatment effectiveness by measuring hospital 
readmission rates and healthcare costs associated with managing people with schizophrenia. 
While these measures have supported the use of LAIs in patients with schizophrenia, there has 
been a disconnect between LAI use and perceptions regarding LAIs.  
 The disadvantage of focusing on quantitative measures is patient-centered care becomes 
less of a priority. This is evidenced by the way both patients and prescribers view the use of 
LAIs. Patients report LAI medications are only offered when they have “failed” oral 
medications. Prescribers are also hesitant to offer LAI medications to patients as they view these 
medications as reserved for patients who have repeated relapses. A lack of education seems to be 
the driver of these misconceptions and through increased awareness both patients and prescribers 
can work to change the perceptions of LAI medications. 
Methodology for the Practice Protocol  
 This is practice change project which involves the developed and implementation of a 
practice protocol for the use of LAIs in the ED.      
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Aim 1: Develop a practice protocol 
 Develop a practice protocol from existing research and clinical evidence with 
algorithms to guide medication management for patients with schizophrenia and other 
psychotic disorders.   
Aim 2: Educate advanced practice providers in ED  
There are three advanced practice providers who provide mental health services in 
the Emergency department who received education about how to use LAIs in the 
emergency department setting. An algorithm of the practice protocol was used as an 
educational tool. An interview was conducted for feedback on provider comfort with 
LAIs and usefulness of protocol at the end of the implementation period.   
Aim 3: Implement protocol 
Twenty patients presented to the ED with a chief compliant of schizophrenia or 
psychosis and were placed in the protocol by the providers. Chart reviews were 
completed to determine if the use of the protocol was effective. The information was 
documented in an electronic medical record (EMR) template which providers attached to 
their daily notes on the patient. No patient identifier information was retained.  
Aim 4: Evaluate providers’ ability to follow protocol and experience  
There are three criteria which were evaluated through documentation. The 
protocol identified patients who met criteria and received the LAI; patients who were 
identified as eligible but did not receive LAI; and provider feedback about their comfort 
level regarding use of LAI’s and opinions about usefulness of the protocol.    
Data collected:  
1. Diagnosis 
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2. Age 
3.  History of having an LAI 
4. Length of stay in ED 
5. Patient response to LAI discussion 
6. Administration of LAI while in the ED 
There are 2 groups of patients who will be included in this protocol: patients who have 
never been on an LAI and those who have been on an LAI in the past but have missed doses. 
This protocol will also assist providers in identifying patient in the ED who would be best suited 
for the implementation of this protocol.  
Setting of the Project 
 A Level 1 trauma center in the southeastern United States which serves both adults and 
children. The department has several specialty areas which include, pediatric emergency 
department, a clinical evaluation unit for medical observation and fast track for those with minor 
illnesses and injuries. There is also a locked psychiatric evaluation unit for mental health 
emergencies. The psychiatric unit is an eight-bed locked and monitored unit.  
 The ED has psychiatry services 24 hours a day 7 day a week. There is a team of providers 
who work with this patient population. The team is made up of advanced practice providers, 
licensed clinical social workers, psychiatry residents and psychiatrists. The team functions as a 
consult service and provides psychiatric evaluation for patients in the ED. The primary focus of 
team was to disposition patients either to inpatient psychiatric hospitals, inpatient substance 
abuse treatment or to discharge home with mental health services. However, this has transitioned 
to providing mental health treatment in addition to the other focuses, as the length of stay has 
increased.  
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Subjects 
 The subjects of the project are the three advanced practice providers who work in the ED 
psychiatry department.  Advanced Practice Providers are made up of nurse practitioners and 
physician assistants. In the ED psychiatry department, they only work with mental health 
patients. These providers are responsible for managing treatment planning for patients who 
present to the ED for a psychiatric complaint. Other providers who work in the ED psychiatry 
department often rotate and they are not consistently in the ED and therefore were not included 
in the implementation. Providers were regular staff in the Emergency Department and who 
worked directly with the population the protocol was targeted for. Each of the providers had at 
least 4 years of practice in the mental health and had been working in the ED for at least 1 year.   
Protocol Implementation and Evaluation  
 While developing the protocol, one of the first obstacles was how to gather the data 
needed to evaluate the protocol. After exploring different options of documentation, developing 
an EMR template would standardize the data being collected as well as making it easier for the 
providers to add it their daily notes. The EMR template included the data discussed above. 
Please appendix B for an example of the EMR template.  
Advanced Practice Providers attended a 1.5-hour educational training about LAIs. The 
training included current guidelines for LAI use. There was a significant amount of time spent on 
LAI initiation and dosing. The providers were also given tips on how to discuss LAI’s with 
patients to help patient better understand LAI treatment. Providers were also educated on how to 
use EMR template to document the discussions they had with the patient. Once 20 patients had 
received the protocol, then the providers were interviewed to discuss their thoughts on the 
protocol.   
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 Advanced Practice Providers were interviewed after the completion of the project to 
discuss ease of the use of the protocol, helpfulness of protocol and comfort with LAI use. 
Descriptive data from chart review will also be gathered to determine if patient discussions about 
LAIs resulted in patient getting an LAI. It also serves to document Pt responses when they refuse 
an LAI and their rationale about this. 
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CHAPTER 4: RESULTS OF PROTOCOL IMPLEMENTATION 
 The protocol outcomes were based on provider responses during a post implementation 
group interview. The first topic discussed was comfort level in using LAIs in treatment planning 
for patients. Providers shared that the 1.5-hour training helped to refresh their knowledge of 
LAIs. However, they shared that their overall knowledge was not increased.  The training also 
did not increase their comfort level regarding the use of the LAI, as they felt they already had the 
knowledge to make those clinician decisions. The providers gained insight from the training in 
that it helped them to recognize that their discussion of LAIs with patients was inconsistent.  
Providers expressed that the protocol was a helpful tool to guide standardization of care related 
to LAIs.   
 They felt the protocol algorithm was easy to use and was helpful in prompting them to 
ask patients about their views about LAIs. They increased their conversations with patients about 
LAIs with patients, and it encouraged them to gather more information about their patient’s 
medical history and previous treatment with and adherence to LAIs. They did not feel pressured 
to make sure a patient received the LAI prior to discharge. However, providers initiated 
discussion of LAIs earlier compared to before receiving education on using the protocol. 
  The EMR template, which prompted the providers to ask questions about LAIs was most 
helpful as it organized the data they needed to collect and made it easier to document relevant 
discussions about LAI history and use. Providers shared that the template was easy to use and 
they were able to add it easily to their daily documentation. It was not time intensive to fill out 
and providers felt it was easy to incorporate into their daily work flow. Providers documented 
23 
their patients’ response to LAI education.  Providers shared this process enabled them to better 
understand the patient’s perception of their treatment.  
 Providers felt the protocol was useful in the ED setting as it increased the discussions 
about the patient preference with regards to medications. Providers shared that discussing and 
documenting patients’ perceptions about medications was helpful.  This allowed them to include 
their patients in in the process of developing their treatment plan. Some of the concerns cited by 
providers in the literature review included the perception of pressuring patients into getting an 
LAI. However, the providers in this protocol did not feel they were pressuring patients to take an 
LAI and felt like they were inclusively opening the door to a discussion about their care.  
 They cited a few barriers to implementation of the protocol. There was not a set time the 
protocol had to be documented. They felt setting a time to complete protocol documentation 
would be helpful so other providers know when to look for it in the documentation. Providers 
suggested optimal times to document the LAI protocol, including admission and 24 hours-post 
admission.  Acuity was also perceived as a barrier as patients may not be able to participate in 
this discussion when they are in crisis.  Some of the LAI information can be received from 
pharmacy and their outpatient providers, but there continues to be a need to work with the patient 
to determine if they are interested prior to being discharged from the ED.    
 The data collected from the patients was used to understand the patient population better 
and to determine if patients received the LAI as a result of the discussion with the provider. 
Patients served by the providers had a mean age of 39 years. The average length of stay for this 
group was 4.8 days. In this group, a total of 70% were non-adherent to their medications. 
Interestingly, 45% of patients were not adherent to their oral medications as opposed to 25% of 
patients on an LAI. About 30% of patients who presented to the ED for psychiatric evaluation 
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were adherent to their medications. The data collected showed 40% of patients who were 
included into the protocol received an LAI prior to leaving the ED. Of the patients who were 
prescribed an LAI by providers who participated in the protocol, 25% were first time recipients 
of LAIs.  The average length of stay for those received an LAI was 6.75 days.   
Limitations    
The most significant limitation was the lack of data to help inform optimal strategies for 
improving processes and outcomes in the ED, including the unavailability of baseline data about 
how often patients were receiving LAIs in the ED. The ED psychiatry team has been working to 
get general data about the number of psychiatric patients seen in the ED, what diagnoses are 
most common and where do these patients end up on discharge. Without baseline data to 
determine the needs for this population, team used their previous experience and insight as 
clinicians to identify the patients they felt might optimally benefit from the implementation of a 
practice protocol based on their experience.  
Prior to the implementation of the protocol, patients were able to receive the LAI, but 
there was no process to encourage ED providers to offer this as an option. This was confirmed 
during the post implementation interview when providers verbalized they were asking about 
LAIs more consistently. Due to a lack of these data, it is difficult to state if the protocol increased 
the number of patients receiving LAIs in the ED or if it improved overall outcomes for the 
patients. 
Another limitation was the fact that the psychiatry team members targeted for this 
implementation project did not fully represent the diversity of healthcare professionals who 
provide care on the ED psychiatry team. This protocol was implemented with advanced practice 
providers (psychiatric mental health nurse practitioners and physicians assistants).  While the 
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advanced practice providers are most constant members of the ED psychiatry team (most of the 
physicians are rotating residents or fellows), there are other clinicians and providers on the team 
who were not a part of the implementation (e.g., social workers). There were patients who may 
have been eligible for the implementation who were not seen by an advanced practice provider 
during their visit.     
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATION FOR PRACTICE 
With increasing length of stays in the ED, it seemed appropriate to look to what inpatient 
psychiatric units having been doing and adapt these interventions to the ED setting. Anecdotally, 
the ED psychiatry team felt patients with psychotic disorders such as schizophrenia stayed in the 
ED longer and were more difficult to stabilize. The use of LAIs is more common on inpatient 
psychiatric units and when a patient is seen in an outpatient clinic, but there is an opportunity to 
offer it to patients in the ED who are remaining in the ED for several days and stabilizing prior to 
getting an inpatient psychiatry bed.  
The conclusions which can be drawn from this DNP project are broad and have 
significant implications for future practice. The implementation of this protocol suggests a 
proactive approach to managing care for patients who present to the ED for a psychiatric 
condition. By initiating treatment sooner in their ED stay, patients who are waiting for inpatient 
hospitalization are getting treatment for the chief complaint they came to the ED for.  
This DNP project has shown practice protocols aims at specific clinical settings, such the 
ED, can improve practice through treatment algorithms and provider training. Findings from this 
project highlight the importance of strategically collecting more data about the demographic and 
baseline status of patients to specifically measure and understand patient-related outcomes 
resulting from the LAI protocol implementation.  Although the objective of this project did not 
include measurement of patient outcomes, future projects could include this as a focus.  The 
protocol also provided the clinical guidelines and recommendations for management of patients 
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with psychotic disorders and allowed the provider to discuss the topic of the LAI with the 
patient and develop the treatment plan based on their clinical judgement.    
Utilizing the EMR to implement practice protocols was effective. EMRs make it easier to 
individualize patient care and to incorporate clinic specific goals. The Emergency Psychiatry 
Department team has few set processes in place to provide care for mental health patients and 
because of this there was an opportunity to examine the care provided. The EMR template 
prompted the providers to supply data for the LAI protocol. Providers felt the template was easy 
to use and increased their use of the protocol as a result. EMRs are also a tool to collect data 
from patient populations for future use which can help in determining the effectiveness of 
practice protocols.  
Future Practice 
 LAIs are an underutilized treatment option for patients with psychotic disorders 
regardless of setting. The ED is an unconventional place to initiate and administer and LAI as 
well. However, when examining the larger picture, the use of LAIs in the ED is a reasonable 
option and may provide patients with improved outcomes as research suggests. For this project, a 
limited number of providers were educated on using the protocol, but as the feedback regarding 
to protocol has been positive, it would be beneficial to explore the option to educate the other 
providers on the ED psychiatry team in order to increase use of the protocol.   
 Research as shown both provider and patient perception of LAIs contributes to the use of 
LAIs. This project has illustrated including patients in the discussion and having an open 
dialogue about their treatment can be a positive experience for both the provider and the patient. 
The need for continued education on the use of LAIs and ways to discuss this treatment option 
with patients will instrumental in changing future practice.   
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 For future practice, the protocol was limited to advanced practice providers so there will 
be a plan to discuss expanding the use of the protocol to the entire disciplinary team. The 
hospital leadership are aware of the DNP project and are interested in the results and how they 
can show improved quality of care for psychiatric patients in the ED.  
Another area of future practice would involve the effectiveness of the protocol. The 
protocol was not designed to demonstrate effectiveness of the LAI in preventing relapse. There 
will be a need to look at outcomes of these patients after they leave the ED setting. This data 
would also contribute to the existing literature regarding LAIs and their effectiveness in 
preventing relapse in patients with psychotic disorders.   
While this protocol was developed based on the patient population and providers in a 
specific setting, practice protocols are versatile and can be adapted to any clinical setting with 
varying resources. In the ED setting, protocols can be helpful in providing guidance to providers 
with limited experience in caring for mental health patients. This may be particularly useful in 
EDs which do not have psychiatry readily accessible.   
Practice protocols are an effective way to translate research in clinical practice and will 
be essential in future practice. These protocols can be easy to implement and give guidance to 
providers who are working with specific populations. For providers working with mental health 
patients in the ED setting, these protocols and can make managing these patients easier. 
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Table 1 
LAI Protocol Data 
Age Diagnosis LOS Hx LAI  
(type)   
Current 
LAI 
Which 
one? 
Adherent 
or not 
Pt 
comments/ 
responses 
Administered 
in ED 
22 TBI with 
behavioral 
disturbances 
2 No, Oral 
risperidon
e 
N/A Not 
adherent 
to PO 
Pt clinically 
unable to 
participate 
No 
37 Schizophrenia  3 No, oral 
Haldol 
No Not 
adherent 
to PO 
Pt is 
agreeable 
Yes 
53 Schizoaffective 
disorder  
2 Yes, 
Prolixin, 
Haldol 
No Non 
adherent 
to PO 
Reports side 
effects of 
forgetfulness 
so stopped 
taking LAI 
No 
28 Schizoaffective 
disorder 
22 Abilify Abilify Yes Helps me Yes 
55 Schizophrenia 7 Yes Haldol 
decanoate 
No, 
missed 
last 
injection 
PT feels on 
too much 
medications, 
but willing to 
take it 
Yes  
27 Schizoaffective 16 No NA NA Not 
interested, 
also does not 
feel she needs 
medications  
 No 
37 Schizoaffective 
disorder  
3 No NA Not 
adherent 
to PO 
Refused 
because she 
did not want 
to take any 
medications 
No 
71 Schizoaffective 
disorder 
2 No N/A Adherent 
to PO 
Pt would be 
open to it, but 
she has never 
been on one 
before and 
would like to 
think about it.  
No 
48 Schizophrenia 1 No NA PO 
adherent 
States he has 
never been 
offered an 
LAI, but open 
to the idea. 
Not on a med 
which can be 
transitioned 
to LAI 
 
No 
29 Schizoaffective 
disorder  
10 Yes, 
Haldol 
Abilify Not 
adherent  
Initially 
refused due to 
psychosis, but 
Yes 
30 
and 
Abilify 
agreed to take 
Abilify LAI 
38 Schizoaffective  1 Yes, 
Prolixin 
decanoate 
Prolixin Non 
adherent 
Per ACTT 
refused, but 
Pt was 
agreeable to 
taking it 
before 
leaving ED 
Yes 
29 Schizoaffective 
disorder 
2 No NA Non 
adherent 
to PO 
Is interested 
in LAI will 
talk to 
provider 
about this 
No 
25 Schizoaffective 5 No NA Non-
adherent 
to PO-
Prolixin 
Agreeable to 
taking 
medication. 
Will take 
Prolixin 
decanoate 
Yes 
53 Schizophrenia 4 
 
Yes , 
Invega 
Sustenna, 
Prolixin 
decanoate 
Yes, 
Invega 
Sustenna, 
Prolixin 
decanoate 
Non-
adherent, 
missed 
dose 
Willing to 
restart  
Yes 
25 Schizoaffective 
disorder  
1 Yes, 
Invega 
Yes Adherent It helps with 
my anger 
No 
43 Schizoaffective 
disorder  
1 Yes, 
Haldol, 
Risperdal 
NA Adherent 
to PO  
Will consider 
this and 
discuss with 
outpatient 
provider  
No 
30 Schizophrenia 2 Yes, 
Invega 
Sustenna  
NA Adherent 
to PO,  
Community 
provider 
requested 
Haldol 
decanoate, PT 
agreed to take 
it   
Yes 
31 Schizoaffective 
disorder  
6  No NA Non 
adherent 
to PO 
Refused 
insisting he 
would only 
take PO  
No 
63 Schizoaffective 
disorder  
5 Yes Haldol PO 
adherent  
States “I 
don’t need 
shots 
anymore 
cause I take 
my pills” 
No 
36 Bipolar 1 Yes 
Abilify 
Abilify Adherent, 
not due 
“Keeps my 
mind clear” 
No 
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Table 2 
Summary Table 
N=20 
 
Age  
      Average Age 39 yrs old 
      Median Age 36.5 yrs old 
  
Diagnosis  
      Schizophrenia 25% 
      Schizoaffective disorder  65% 
      Other 10% 
  
Length of stay (days)  
       Average 4.8 days 
       Median 2.5 days 
  
History of LAI 50% 
  
Current LAI 40% 
  
Antipsychotic Non-Adherence  
       Oral   45% 
       LAI 25% 
       Total 70% 
  
Received LAI in ED  N= 8 
        History of LAI  N= 6 (75%) 
        No history of LAI  N= 2 (25%) 
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Table 3 
Provider Interview Responses 
Question Responses 
How comfortable do you feel about 
developing treatment plan using LAIs 
I felt comfortable using LAIs prior to this, so 
there was no change in my comfort level 
 
I think we are using LAIs more 
Do you feel your ability to discuss LAIs with 
patient has improved? 
I think my ability has remained the same, but 
protocol prompted me to ask patients who I 
might not have asked 
 
I did not feel I had difficulty discussing it, but 
I wasn’t doing it consistently 
Did you feel the protocol algorithm was easy 
to use? 
Yes, it was helpful in organizing the 
information about LAIs 
 
It helped remind me to ask about LAIs 
  
Was the dot phrase helpful in LAI treatment 
planning? 
It helped with assessing previous experienced 
with LAI 
 
The patient response was interesting and 
allowed to me help discuss and understand 
patient concerns about LAI’s 
 
Easy to add into my daily notes.  
How useful was the protocol in the ED 
setting? 
Helpful in prompting the discussion about the 
medications 
 
There was no pressure to give the medications 
if the patient did not want it, made it easier to 
have the discussion  
What were the barriers you encountered with 
the protocol? 
Acuity can make it difficult to have 
discussion about this 
 
Unsure if anyone else has done the 
assessment 
 
In ED it is sometimes hard to determine if 
there is true psychosis or if substances are the 
cause, hesitant to have the discussion with 
those patients 
Suggestions for improvement  Create set time to discuss LAIs like on 
admission or on first reassessment after 
patient has been there 24 hrs.  
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Table 4 
 
Patient responses to provider discussions 
Patient responses  Received LAI in ED 
Pt clinically unable to participate, guardian agreed 
to LAI 
No 
Pt is agreeable Yes 
Reports side effects of forgetfulness so stopped 
taking LAI 
No 
“Helps me” Yes 
Pt feels on too much medications, but willing to 
take it 
Yes  
Not interested, also does not feel she needs 
medications  
 No 
Refused because she did not want to take any 
medications 
No 
Pt would be open to it, but she has never been on 
one before and would like to think about it.  
No 
States he has never been offered an LAI, but open 
to the idea. Not on a med which can be 
transitioned to LAI 
 
No 
Initially refused due to psychosis, but agreed to 
take Abilify LAI 
Yes 
Per ACTT refused, but Pt was agreeable to taking 
it before leaving ED 
Yes 
Is interested in LAI will talk to provider about this No 
Agreeable to taking medication. Will take Prolixin 
decanoate 
Yes 
Willing to restart  Yes 
It helps with my anger No 
Will consider this and discuss with outpatient 
provider  
No 
Community provider requested Haldol decanoate 
and patient agreed to take it 
Yes 
Refused insisting he would only take PO  No 
States “I don’t need shots anymore cause I take 
my pills” 
No 
“My Abilify keeps my mind clear”  No 
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Appendix A 
 
Provider Educational Training 
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Appendix B 
 
 
EMR Template 
 
History of Long acting injectable antipsychotic (LAI)?  
 Option 1: yes 
 Option 2: no 
 
Is patient currently on an LAI? If so which one?  
 Option 1: yes 
 Option 2: no 
 
Last Dose: insert date here 
 
Was LAI Treatment discussed? 
  Option 1: No patient unable to participate in treatment planning 
Option 2: Yes, Pt is not interested at this time 
Option 3: Yes, Pt is interested 
 
Pt response to LAI Discussion: 
 Option 1: Insert patient’s comments about discussion   
 
LAI administered in ED? If yes, data administered:  
 Option 1: Yes, add date 
 Option 2: No 
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Appendix C 
 
Overview of LAI Protocol Flow Diagram 
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Appendix D 
 
LAI Conversion Tool 
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